#Israel #Tel Aviv #Allergy Treatment #Nasus Pharma #FMXIN002

Nasus Pharma Announces Clinical Study Results at AAAAI 2025

Nasus Pharma Ltd., a pioneering biopharmaceutical company focused on innovative, needle-free intranasal therapies, is set to present its promising clinical research on FMXIN002 (also known as NS002) during the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. Held from February 28 to March 3 in San Diego, California, this annual gathering will showcase breakthroughs in allergy and immunology, and Nasus Pharma aims to highlight its valuable contributions in the field.

About FMXIN002

FMXIN002 is an innovative powdered formulation of epinephrine delivered via the intranasal route. This approach has been developed by Nasus Pharma using unique proprietary technology designed to ensure rapid, accessible, and effective treatment for acute allergic reactions. Unlike traditional self-injectors, FMXIN002 aims to provide a quicker response time in emergency situations, which could be life-saving for the approximately 5 million individuals in the United States at risk of severe allergic reactions, particularly anaphylaxis.

Clinical Study Details

The presentation at AAAAI will include thorough discussions on the efficacy and safety of FMXIN002, based on two clinical studies that encompass both pharmacokinetics and pharmacodynamics. Data will be shared from trials conducted with healthy volunteers and those under allergenic conditions among atopic patients. This integrated analysis is intended to illustrate the potential advantages of FMXIN002 over existing treatments.

"We are thrilled to disseminate our groundbreaking findings at an esteemed event like AAAAI. This platform facilitates important dialogue with healthcare professionals, which is crucial as we advance our Epinephrine program to address the significant medical needs faced by those with severe allergies," expressed Dan Teleman, the company's CEO.

Presentation Details

The details of the poster presentation are as follows:

• - Date: March 1, 2025
• - Time: 9:45 AM - 10:45 AM PST
• - Title: Fast Acting, 5 years stable Intra-Nasal Powder Spray Epinephrine for Anaphylaxis: Integrated Analysis of Two Clinical Trials
• - Authors: Tair Lapidot, PhD; Yuval Tal, MD, PhD; Dalia Megiddo, MD; Galia Temtsin Krayz, PhD; Yoseph Caraco, MD
• - Poster ID: 293

The Importance of Intranasal Delivery

Intranasal drug delivery is regarded as particularly beneficial in emergency scenarios where prompt treatment is critical. The system employed by Nasus Pharma not only enhances the speed of drug delivery but also offers a user-friendly experience—crucial attributes in urgent medical situations. The APTAR Nasal Unidose Powder device allows for efficient, easy-to-administer dosing that may mitigate the hesitance associated with current epinephrine injectors.

Conclusion

The importance of immediate access to treatment during anaphylactic events cannot be overstated. As Nasus Pharma continues to progress its intranasal drug delivery innovations, the forthcoming presentation at the AAAAI meeting marks a significant milestone. Attendees are encouraged to visit the poster session to engage with the research and explore the future of allergy treatment solutions.

For further details about Nasus Pharma's developments and insights, stakeholders are welcome to view the abstracts and additional information available on the AAAAI's official meeting website.

For further inquiries, please contact Nasus Pharma Ltd. or visit our website at Nasus Pharma.